Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly. While the Phase 2 trial is still ongoing, Amgen is already planning to run a broad Phase 3 program and scale up manufacturing “with both clinical and commercial supply in mind,” Chief Executive Bob Bradway said on an earnings call.
advertisement
Even though executives shared no data from the interim analysis of its injectable drug, excitement around the molecule has already sent Amgen’s stock up 12% Friday.
Compared with usual care, an Australian modeling study found that a structured program of education and exercise for people with osteoarthritis (OA) of the knee
This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.
SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing
4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly. While the Phase 2 trial is still ongoing, Amgen is already planning to run a broad Phase 3 program and scale up manufacturing “with both clinical and commercial supply in mind,” Chief Executive Bob Bradway said on an earnings call.
advertisement
Even though executives shared no data from the interim analysis of its injectable drug, excitement around the molecule has already sent Amgen’s stock up 12% Friday.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
View All Plans
Exercise, Education to Relieve Knee OA: Mixed Results in Modeling Study
Compared with usual care, an Australian modeling study found that a structured program of education and exercise for people with osteoarthritis (OA) of the knee
Investigating the efficacy and safety of existing drugs in patients with rare immune diseases
This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology | Psychedelic Invest
SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing